UCB's Global Corporate Website
Welcome to UCB in the United States

Aug

11

Setting New Standards in Diversity for Dermatology Clinical Trials

One place where we can learn more about psoriasis in people of color is in clinical trials. However, people with skin of color are drastically underrepresented in clinical trials for dermatology. The lack of diversity in clinical trials means that medications developed for conditions like psoriasis may not work as effectively for people with skin of color, and ultimately, the health equity gap continues to widen.

 

Mar

26

New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

Mar

25

UCB at the 2022 AAD Annual Meeting: Our Commitment to Advancing Science in Dermatology

 

 

Jan

21

Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

Jan

18

Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study

Nov

19

Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms

Oct

22

UCB Presents Number Needed to Treat Analysis for Bimekizumab in Moderate to Severe Plaque Psoriasis at AMCP Nexus

UCB today announced new data from a network meta-analysis (NMA) demonstrating that bimekizumab was associated with the lowest number needed to treat (NNT) to achieve Psoriasis Area and Severity Index (PASI) 90 and PASI 100 skin clearance levels compared with 12 other approved biologic therapies used for moderate to severe plaque psoriasis within 16 weeks. These results were presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2021, October 18-21. 

Oct

16

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

Jun

12

Press Release: First Presentations of Bimekizumab Phase 3 Data Demonstrate Superior Skin Clearance Over Placebo and Stelara at Week 16 in Adults with Moderate-to-Severe Plaque Psoriasis

• Data from the Phase 3 BE VIVID and BE READY studies show that bimekizumab-treated patients with psoriasis achieved significant skin clearance at week 16, rapid response after one dose, and durability of response up to a year
• Results support the importance of selectively inhibiting IL-17F, in addition to IL-17A, with bimekizumab

PsO_Patient_1280x960

Aug

01

Disease Spotlight: Psoriasis

August is Psoriasis Awareness Month so we’re shining a spotlight on the disease and how UCB is working to deliver solutions that patients value.